Circovirus Hepatitis in Immunocompromised Patient, Switzerland
Baptiste Hamelin
1, Philippe Pérot
1, Ian Pichler
1, Jasmin D. Haslbauer, David Hardy, David Hing, Sarra Loulizi, Béatrice Regnault, Anouk Pieters, Ingmar Heijnen, Caroline Berkemeier, Maria Mancuso, Verena Kufner, Niels Willi, Anne Jamet, Nolwenn Dheilly, Marc Eloit, Mike Recher, Michael Huber
2, and Kirsten D. Mertz
2
Author affiliations: Cantonal Hospital Baselland, Liestal, Switzerland (B. Hamelin, M. Mancuso, N. Willi, K.D. Mertz); University Hospital Basel, Basel, Switzerland (B. Hamelin, J.D. Haslbauer, I. Heijnen, C. Berkemeier, M. Mancuso, N. Willi, M. Recher, K.D. Mertz); Institut Pasteur, Paris, France (P. Pérot, D. Hardy, D. Hing, S. Loulizi, B. Regnault, N. Dheilly, M. Eloit); University of Zurich, Zurich, Switzerland (I. Pichler, V. Kufner, M. Huber); University of Basel Department of Biomedicine, Basel (A. Pieters, M. Recher, K.D. Mertz); Assistance Publique–Hôpitaux de Paris Centre Université de Paris Cité Necker-Enfants Malades Hospital, Paris (A. Jamet)
Main Article
Figure 4
Figure 4. Human circovirus 1 viral loads in recently collected and archival samples (2023 and 2024) compared with viral load in initial liver biopsy (2022) from a hepatitis patient, Switzerland. Virus copies and log virus copies were also tabulated (Appendix Table 3).
Main Article
Page created: August 13, 2024
Page updated: September 23, 2024
Page reviewed: September 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.